Acelyrin, a drug developer for inflammatory diseases that has raised $550 million since its founding two years ago, fortified its leadership team by hiring Mina Kim as its first chief legal and administrative officer.

Kim is joining Woodland Hills, California-based Acelyrin from synthetic biotechnology company Zymergen, where she was chief legal officer and head of corporate development. The company was sold to Ginkgo Bioworks last month after pipeline setbacks wiped out nearly all its stock market value.